Oncogenic Ras/ERK signaling activates CDCP1 to promote tumor invasion and metastasis

Molecular Cancer Research

Volumn 12, Issue 10, 2014, Pages 1449-1459

  Uekita, Takamasa ^a,b   Fujii, Satoko ^a   Miyazawa, Yuri ^a   Iwakawa, Reika ^a   Narisawa Saito, Mako ^a   Nakashima, Katsuhiko ^a   Tsuta, Koji ^c   Tsuda, Hitoshi ^c   Kiyono, Tohru ^a   Yokota, Jun ^a   Sakai, Ryuichi ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b NATIONAL DEFENSE ACADEMY   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CUB DOMAIN CONTAINING PROTEIN 1; GELATINASE A; GELATINASE B; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN TYROSINE KINASE; RAS PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; CDCP1 PROTEIN, HUMAN; CELL ADHESION MOLECULE; LEUKOCYTE ANTIGEN; MATRIX METALLOPROTEINASE; TUMOR PROTEIN;

ANOIKIS; ARTICLE; CARCINOGENESIS; CELL MIGRATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CANCER CELL LINE; METASTASIS; NON SMALL CELL LUNG CANCER; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR INVASION; UTERINE CERVIX CANCER; CELL MOTION; GENETICS; LUNG TUMOR; MALE; METABOLISM; MUTATION; NEOPLASM; ONCOGENE RAS; PATHOLOGY; TUMOR CELL LINE;

ANOIKIS; ANTIGENS, CD; CARCINOMA, NON-SMALL-CELL LUNG; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CELL MOVEMENT; GENES, RAS; HUMANS; LUNG NEOPLASMS; MALE; MAP KINASE SIGNALING SYSTEM; MATRIX METALLOPROTEINASES; MUTATION; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASMS; SRC-FAMILY KINASES;

EID: 84907965104     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-13-0587     Document Type: Article

References (50)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
2. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-9.
3. Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet 1993;9:138-41.
4. Smakman N, Borel Rinkes IH, Voest EE, Kranenburg O. Control of colorectal metastasis formation by K-Ras. Biochem Biophys Acta 2005;1756:103-14.
5. Downward J. Targeting RAS signaling pathways in cancer therapy. Nat Rev Cancer 2003;3:11-22.
6. Hooper JD, Zijlstra A, Aimes RT, Liang H, Claassen GF, Tarin D, et al. Subtractive immunization using highly metastatic human tumor cells identifies SIMA135/CDCP1, a 135 kDa cell surface phosphorylated glycoprotein antigen. Oncogene 2003;22:1783-94.
7. Brown TA, Yang TM, Zaitsevskaia T, Xia Y, Dunn CA, Sigle RO, et al. Adhesion or plasmin regulates tyrosine phosphorylation of a novel membrane glycoprotein p80/gp140/CUB domain-containing protein 1 in epithelia. J Biol Chem 2004;279:14772-83.
8. Bhatt AS, Erdjument-Bromage H, Tempst P, Craik CS, Moasser MM. Adhesion signaling by a novel mitotic substrates of src kinases. Oncogene 2005;24:5333-43.
9. Uekita T, Jia L, Narisawa-Saito M, Yokota J, Kiyono T, Sakai R. CUB domain-containing protein 1 is a novel regulator of anoikis resistance in lung adenocarcinoma. Mol Cell Biol 2007;27:7649-60.
10. Benes CH, Wu N, Elia AE, Dharia T, Cantley LC, Soltoff SP. The C2 domain of PKCd is a phosphotyrosine binding domain. Cell 2005;121:271-80.
11. Miyazawa Y, Uekita T, Hiraoka N, Fujii S, Kosuge T, Kanai Y, et al. CUB domain-containing protein 1, a prognostic factor for human pancreatic cancers, promotes cell migration and extracellular matrix degradation. Cancer Res 2010;70:5136-46.
12. Uekita T, Tanaka M, Takigahira M, Miyazawa Y, Nakanishi Y, Kanai Y, et al. CUB-domain-containing protein 1 regulates peritoneal dissemination of gastric scirrhous carcinoma. Am J Pathol 2008;172:1729-39.
13. Casar B, Rimann I, Kato H, Shattil SJ, Quigley JP, Deryugina EI. In vivo cleaved CDCP1 promotes early tumor dissemination via complexing with activated β1 integrin and induction of FAK/PI3K/Akt motility signaling. Oncogene 2014;33:255-68.
14. Law ME, Corsino PE, Jahn SC, Davis BJ, Chen S, Patel B, et al. Glucocorticoids and histone deacetylase inhibitors cooperate to block the invasiveness of basal-like breast cancer cells through novel mechanisms. Oncogene 2013;32:1316-29.
15. Awakura Y, Nakamura E, Takahashi T, Kotani H, Mikami Y, Kadowaki T, et al. Microarray-based identification of CUB-domain containing protein 1 as a potential prognostic maker in conventional renal cell carcinoma. J Cancer Res Clin Oncol 2008;134:1363-9.
16. Ikeda JI, Oda T, Inoue M, Uekita T, Sakai R, Okumura M, et al. Expression of CUB domain containing protein (CDCP1) is correlated with prognosis and survival of patients with adenocarcinoma of lung. Cancer Sci 2009;100:429-33.
17. Uekita T, Fujii S, Miyazawa Y, Hashiguchi A, Abe H, Sakamoto M, et al. Suppression of autophagy by CDCP1 signaling is essential for anchor-age-independent survival of Lung cancer cells. Cancer Sci 2013;104:865-70.
18. Iwakawa R, Okayama H, Kohno T, Sato-Otsubo A, Ogawa S, Yokota J. Contribution of germline mutations to PARK2 gene inactivation in lung adenocarcinoma. Genes Chromosomes Cancer 2012;51:462-72.
19. Iwakawa R, Kohno T, Enari M, Kiyono T, Yokota J. Prevalence of human papilloma virus 16/18/33 infection and p53 mutation in lung adenocarcinoma. Cancer Sci 2010;101:1891-6.
20. Narisawa-Saito M, Yoshimatsu Y, Ohno S, Yugawa T, Egawa N, Fujita M, et al. An in vitro multistep carcinogenesis model for human cervical cancer. Cancer Res 2008;68:5699-705.
21. Takahashi Y, Hiraoka N, Onozato K, Shibata T, Kosuge T, Nimura Y, et al. Solid-pseudopapillary neoplasms of the pancreas in men and women: do they differ? Virchows Arch 2006;448:561-9.
22. Miyoshi H, Blomer U, Takahashi M, Gage FH, Verma IM. Development of a self-inactivating lentivirus vector. J Virol 1998;72:8150-7.
23. Uekita T, Gotoh I, Kinoshita T, Itoh Y, Sato H, Shiomi T, et al. Membrane-type 1 matrix metalloproteinase cytoplasmic tail-binding protein-1 is a new member of the cupin superfamily. J Biol Chem 2004;279:12734-43.
24. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, et al. A matrix metalloproteinase expressed on the surface of invasive tumor cells. Nature 1994;370:61-5.
25. Scherl-Mostageer M, Sommergruber W, Abseher R, Hauptmann R, Ambros P, Schweifer N. Identification of a novel gene, CDCP1, overexpressed in human colorectal cancer. Oncogene 2001;20:4402-8.
26. Iwakawa R, Kohno T, Kato M, Shiraishi K, Tsuta K, Noguchi M, et al. MYC amplification as a prognostic maker of early-stage lung adenocarcinoma identified by whole genome copy number analysis. Clin Cancer Res 2011;17:1482-9.
27. Matsumoto S, Takahashi K, Iwakawa R, Matsuno Y, Nakanishi Y, Kohno T, et al. Frequent EGFR mutations in brain metastases of lung adenocarcinoma. Int J Cancer 2006;119:1491-4.
28. Blanco R, Iwakawa R, Tang M, Kohno T, Angulo B, Pio R, et al. A genealteration profile of human lung cancer cell lines. Hum Mutat 2009;30:1199-206.
29. MacAuley A, Pawson T. Cooperative transforming activities of ras, myc, and src viral oncogenes in nonestablished rat adrenocortical cells. J Virol 1988;62:4712-21.
30. Shields DJ, Murphy EA, Desgrosellier JS, Mielgo A, Lau SK, Barnes LA, et al. Oncogenic Ras/Src cooperativity in pancreatic neoplasia. Oncogene 2011;30:2123-34.
31. Liu H, Ong SE, Badu-Nkansah K, Schindler J, White FM, Hynes RO, et al. CUB-domain-containing protein 1 (CDCP1) activates src to promote melanoma metastasis. Proc Natl Acad Sci U S A 2011;108:1379-84.
32. Gialeli C, Theocharis AD, Karamanos NK. Role of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 2010;278:16-27.
33. Cha HJ, Bae SK, Lee HY, Lee OH, Sato H, Seiki M, et al. Anti-invasive activity of ursolic acid correlateswith the reduced expression of matrix metalloproteinase-9 (MMP-9) in HT1080 human fibrosarcoma cells. Cancer Res 1996;56:2281-4.
34. Kinjo T, Ye J, Yan H, Hamasaki T, Nakanishi H, Toh K, et al. Suppressive effects of electrochemically reduced water on matrix metalloproteinase-2 activities and in vitro invasion of human fibrosarcoma HT1080 cells. Cytotechnology 2012;64:357-71.
35. Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. J National Cancer Inst 2001;9:1062-74.
36. Shields JM, Pruitt K, McFall A, Shaub A, Der CJ. Understanding RAS: 'it ain't over 'til it's over. Trends Cell Biol 2000;10:147-54.
37. Razorenova OV, Finger EC, Colavitti R, Chernikova SB, Boiko AD, Chan CK, et al. VHL loss in renal cell carcinoma leads to up-regulation of CUB domain-containing protein 1 to stimulate PKCd-driven migration. Proc Natl Acad Sci U S A 2011;108:1931-6.
38. Richard DE, Berra E, Gothié E, Roux D, Pouysségur JJ. P42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1α (HIF-1α) and enhance the transcriptional activity of HIF1. J Biol Chem 1999;274:32631-7.
39. Whitmarsh AJ, Davis RJ. Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathway. J Mol Med 1996;74:589-607.
40. Benes CH, Poulogiannis G, Cantley LC, Soltoff SP. The Src-associated protein CUB domain-containing protein-1 regulates adhesion and motility. Oncogene 2012;31:653-63.
41. Zheng Y, Xia Y, Hawke D, Halle M, Tremblay ML, Gao X, et al. FAK phosphorylation by ERK primes Ras-induced tyropsine dephosphorylation of FAK mediated by PIN1 and PTP-PEST. Mol Cell 2009;35:11-25.
42. Lee SK, Kim JM, Lee MY, Son KH, Yeom YI, Kim CH, et al. Con firmation of linkage between H-Ras and MMP-13 expression as well as MMP-9 by chemical genomic approach. Int J Cancer 2006;118:2172-81.
43. Miyazawa Y, Uekita T, Ito Y, Seiki M, Yamaguchi H, Sakai R. CDCP1 regulates the function of MT1-MMP and invadopodia-mediated invasion of cancer cells. Mol Cancer Res 2013;11:628-37.
44. De Rook W, Lambrechts D, Tejpar S. K-ras mutations and cetuximab in colorectal cancer. N Engl J Med 2009;360:834-6.
45. Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005;2:e17.
46. Sakuma Y, Matsukuma S, Yoshihara M, Nakamura Y, Noda K, Nakayama H, et al. Distinctive evaluation of nonmucinous and mucinous subtypes of branchioloalveolar carcinomas in EGFR and K-ras gene-mutation analyses for Japanese lung adenocarcinoma. Am J Clin Oncol 2007;128:100-8.
47. Dong Y, He Y, de Boer L, Stack MS, Lumley JW, Clements JA, et al. The cell surface glycoprotein CUB domain-containing protein 1 (CDCP1) contributes to epidermal growth factor receptor mediated cell migration. J Biol Chem 2012;287:9792-803.
48. Burnham MR, Bruce-Staskal PJ, Harte MT, Weidow CL, Ma A, Weed SA, et al. Regulation of c-Src activity and function by the adapter protein Cas. Mol Cell Biol 2000;20:5865-78.
49. Tanaka M, Sasaki K, Kamata R, Hoshino Y, Yanagihara K, Sakai R. A novel RNA-binding protein, Ossa/C9orf10, regulates activity of Src kinases to protect cells from oxidative stress-induced apoptosis. Mol Cell Biol 2008;29:402-13.
50. Spassov DS, Wong CH, Harris G, McDonough S, Phojanakong P, Wang D, et al. A tumor-suppressing function in the epithelial adhesion protein Trask. Oncogene 2012;31:419-31.